Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury

Marcus J Schultz, Marcel Levi

The role and source of tissue factor

A large body of evidence has shown that systemic coagulopathy is a key event in severe systemic inflammation, such as that which occurs in sepsis. Systemic coagulopathy is the net result of activation of coagulation and defective systems of natural inhibition of coagulation, on the one hand, and attenuation of fibrinolysis on the other. Activation of coagulation is primarily driven by the extrinsic coagulation pathway which starts with expression of tissue factor (TF) on mononuclear cells and endothelial cells. TF then binds and activates factor VII which activates downstream coagulation cascades. Mechanisms that regulate the coagulation pathway under normal conditions involve natural inhibitors of coagulation, including activated protein C (APC), antithrombin (AT) and tissue factor pathway inhibitor (TFPI). In general, they all interfere with the TF–factor VIIa-induced activation of coagulation, but on different levels. In patients with sepsis, increased coagulant activity is not sufficiently counterbalanced by these natural inhibitors. In addition, a rapid sustained increase in synthesis of plasminogen activator inhibitor (PAI)-1 is present during the septic response. PAI-1 is the main inhibitor of tissue-type and urokinase-type plasminogen activator (tPA and uPA) which activate the fibrinolytic system. The importance of systemic coagulopathy with sepsis has been established in experimental studies and in the randomised, prospective, double-blind, placebo-controlled PROWESS trial in which infusion of recombinant human (rh)-APC resulted in improved survival of patients with severe sepsis.

LOCAL COAGULOPATHY WITH ACUTE LUNG INJURY

Coagulopathy with acute lung injury and/or pneumonia

Recent studies have clearly shown that prominent changes in local fibrin turnover are an important feature of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and pulmonary infec-

Ventriculoperitoneal coagulopathy

Compelling evidence from preclinical and clinical studies shows that mechanical ventilation aggravates or may even initiate lung injury. The similarities between the inflammatory responses in pneumonia and ALI/ARDS suggest that similar changes in coagulation and fibrinolysis may occur in ventilator-induced lung injury. The knowledge on ventilator-induced coagulopathy is rapidly growing. Several preclinical studies and one clinical study in healthy subjects suggest that pulmonary fibrin turnover is indeed influenced by mechanical ventilation. Some suggestion on the existence of TF-mediated coagulation caused by mechanical ventilation comes from a preliminary report on short-term mechanical ventilation in patients undergoing a surgical procedure. In addition, small but consistent changes in pulmonary coagulation in mice have been found with injurious forms of mechanical ventilation (Wolthuis, unpublished data). Only two preclinical studies have focused on the effect of mechanical ventilation on pulmonary fibrinolysis, in which it was found that injurious mechanical ventilation attenuates fibrinolytic activity in rats, which appears to be caused by increased production and/or release of PAI-1.

SOURCE OF TF IN ALVEOLAR SPACES

One limitation with all studies on pulmonary coagulopathy so far is that they do not give sufficient insight into the potential sources of TF in the alveolar spaces. It has been suggested that changes in coagulation and fibrinolysis found in the pulmonary compartment are the result of leakage of coagulation factors into the lungs from the systemic circulation. Indeed, concordant increased activation of coagulation in the systemic compartment was found with infectious pulmonary coagulopathy in one study. However, TF is not present in the systemic circulation. In addition, pulmonary infection was characterised by local (but not systemic) attenuation of fibrinolysis, suggesting that pulmonary coagulopathy is a localised process.

In this issue of Thorax, Bastarache et al report their findings on the ability of the alveolar epithelium to initiate intra-alveolar coagulation by expressing active TF (see page 608). Using an in vitro cell surface TF assay and TF ELISA, they measured the production and activity of TF in cultured alveolar epithelial cells following exposure to different stimuli. TF activity, mRNA and protein levels increased in A549 cells after stimulation with an pro-inflammatory stimulus (cyto-

momix). Importantly, increased TF activity was also measured following incubation with pulmonary oedema fluid from
patients with ALI/ARDS. Furthermore, immunohistochemistry for TF in human lung tissue from patients with ALI/ARDS showed prominent TF staining in alveolar epithelial cells as well as intra-alveolar macrophages and hyaline membranes. Given the markedly increased levels in pulmonary edema fluid compared with plasma, it strongly suggests that there is an intra-alveolar source of TF. The reported findings further provide convincing evidence that the alveolar epithelium can initiate TF-dependent intra-alveolar coagulation in this disease setting. The major strengths of the study include the use of a well-characterised and large cohort of patients with ALI/ARDS with an appropriate control group, the use of co-staining with a type II epithelial cell marker in the immunohistochemical studies and the fact that TF measurements were performed on undiluted pulmonary edema fluid rather than using BAL fluid, thus avoiding potential complications due to dilution effects. One weakness of the study is that the investigators did not study alveolar macrophages, as it has been shown that alveolar macrophages from humans contain procoagulant activity. Also, they did not consider the pulmonary vascular endothelium as a potential source of TF during pulmonary inflammation.

**CONCLUSION**

Alveolar fibrin deposition is an important feature of pulmonary infection or inflammation. Some studies also suggest that pulmonary coagulopathy is a feature of ventilator-induced lung injury. Mechanisms that contribute to this fibrin deposition are localised thrombin generation and depression of bronchoalveolar fibrinolysis. Remarkably, changes in alveolar coagulation and fibrinolysis closely resemble those found systemically in patients with sepsis. Recent studies have demonstrated the beneficial effect of anticoagulant therapy in sepsis. Theoretical considerations suggest novel therapeutic strategies or preventive measures in critically ill patients, but clinical studies are needed to examine this hypothesis.


doi: 10.1136/thx.2006.07256

---

**Authors’ affiliations**

Marcus J Schultz, Department of Intensive Care Medicine and Laboratory of Experimental Intensive Care and Anaesthesiology (LEICA), Academic Medical Center - University of Amsterdam, and HERMES Critical Care Group, Amsterdam, The Netherlands

Marcus Levi, Department of Internal Medicine, Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands

Correspondence to: Dr Marcus J Schultz, Department of Intensive Care Medicine, C3-415, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; m.j.schultz@amc.uva.nl

Competing interests: None.

**REFERENCES**


Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury

Marcus J Schultz and Marcel Levi

*Thorax* 2007 62: 563-564
doi: 10.1136/thx.2006.067256

Updated information and services can be found at:
http://thorax.bmj.com/content/62/7/563

These include:

**References**
This article cites 30 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/62/7/563#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- TB and other respiratory infections (1273)
- Inflammation (1020)
- Adult respiratory distress syndrome (111)
- Mechanical ventilation (158)
- Lung infection (97)
- Mechanical ventilation (171)
- Airway biology (1100)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/